CUMYL-3TMS-PRINACA

CUMYL-3TMS-PRINACA
Identifiers
	IUPAC name N-(2-phenylpropan-2-yl)-1-(3-(trimethylsilyl)propyl)-1H-indazole-3-carboxamide;
Chemical and physical data
Formula	C23H31N3OSi
Molar mass	393.606 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[Si](C)(C)CCCn1nc(C(=O)NC(C)(C)c2ccccc2)c2ccccc12;
	InChI InChI=1S/C23H31N3OSi/c1-23(2,18-12-7-6-8-13-18)24-22(27)21-19-14-9-10-15-20(19)26(25-21)16-11-17-28(3,4)5/h6-10,12-15H,11,16-17H2,1-5H3,(H,24,27); Key:BFLYAEBVCZMSPK-UHFFFAOYSA-N;

CUMYL-3TMS-PRINACA is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first identified in Sweden in May 2023. Along with the related compound ADMB-3TMS-PRINACA that was reported several months earlier, CUMYL-3TMS-PRINACA is one of the only psychoactive drugs ever reported that contains a silicon atom.^[1] Another example of a silicon-containing drug is sila-haloperidol.^[2]

Legality

CUMYL-3TMS-PRINACA is illegal in Germany and Italy and has been recommended for control in Sweden.^[3]^[4]

References

^ "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.
^ Tacke R, Popp F, Müller B, Theis B, Burschka C, Hamacher A, et al. (2008). "Sila-haloperidol, a silicon analogue of the dopamine (D2) receptor antagonist haloperidol: synthesis, pharmacological properties, and metabolic fate". ChemMedChem. 3 (1): 152–164. doi:10.1002/cmdc.200700205. PMID 18022977.
^ Terp G (26 May 2023). "Yttrande enligt 13 § Lag (2011:111) om förstörande av vissa hälsofarliga missbrukssubstanser" [Opinion according to § 13 Act (2011:111) re destruction of certain health hazards substances of abuse] (PDF). Folkhälsomyndigheten (The Public Health Authority) (in Swedish).
^ "DECRETO 12 dicembre 2023". Gazzetta Ufficiale (in Italian). 12 December 2023. Update of the tables containing the indication of narcotic and psychotropic substances, pursuant to the decree of the President of the Republic of 9 October 1990, n. 309 and subsequent amendments and additions. Inclusion in Table I of the specific indication of the substances: MDMB-BINACA; N-sec-butyl-pentedrone; CUMIL-3TMS-PRINACA. (23A06995) (GU General Series n.300 of 27-12-2023)

[1] "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.

[2] Tacke R, Popp F, Müller B, Theis B, Burschka C, Hamacher A, et al. (2008). "Sila-haloperidol, a silicon analogue of the dopamine (D2) receptor antagonist haloperidol: synthesis, pharmacological properties, and metabolic fate". ChemMedChem. 3 (1): 152–164. doi:10.1002/cmdc.200700205. PMID 18022977.

[3] Terp G (26 May 2023). "Yttrande enligt 13 § Lag (2011:111) om förstörande av vissa hälsofarliga missbrukssubstanser" [Opinion according to § 13 Act (2011:111) re destruction of certain health hazards substances of abuse] (PDF). Folkhälsomyndigheten (The Public Health Authority) (in Swedish).

[4] "DECRETO 12 dicembre 2023". Gazzetta Ufficiale (in Italian). 12 December 2023. Update of the tables containing the indication of narcotic and psychotropic substances, pursuant to the decree of the President of the Republic of 9 October 1990, n. 309 and subsequent amendments and additions. Inclusion in Table I of the specific indication of the substances: MDMB-BINACA; N-sec-butyl-pentedrone; CUMIL-3TMS-PRINACA. (23A06995) (GU General Series n.300 of 27-12-2023)

[1]

[2]

[3]

[4]

Legality

See also

References